Tech Company Inital Public Offerings
Stealth BioTherapeutics IPO
Stealth BioTherapeutics, based in Newton, debuted as a public company on 2/14/2019.
Transaction Overview
Company Name
Announced On
2/14/2019
Transaction Type
IPO
Amount
$78,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $25.0 million to fund the continued clinical development of elamipretide for the treatment of primary mitochondrial myopathy through pivotal data from a Phase 3 clinical trial; approximately $8.0 million to fund the continued clinical development of elamipretide for the treatment of Barth and LHON through anticipated upcoming regulatory interactions; approximately $8.0 million to fund the continued clinical development of elamipretide for the treatment of dry AMD through initiation of a Phase 2b clinical trial; approximately $6.0 million to fund the continued preclinical development of SBT-272 through IND-enabling studies and to fund a Phase 1 safety trial; approximately $10.4 million for principal and interest payments that we are obligated to make over the next 12 months under our term loan facility with Hercules; and the balance for working capital and other general corporate pur
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
275 Grove St. 3-107
Newton, MA 02466
USA
Newton, MA 02466
USA
Phone
Website
Email Address
Overview
Stealth BioTherapeutics (Nasdaq: MITO) is an innovative biopharmaceutical company committed to bringing patients mitochondria-targeted therapies to treat both common and rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Reenie McCarthy
Chief Financial Officer
Daniel Geffken
Chief Scientific Officer
Mark Bamberger
Vice President
Deb Gouveia
VP - Bus. Development
Brian Blakey
VP - General Counsel
Henry Hess
VP - Operations
Marty Redmon
VP - Regulatory Affairs
David Schubert
Browse more venture capital transactions:
Prev: 2/14/2019: Joor venture capital transaction
Next: 2/14/2019: Socotra venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs